*B. Signing of the Charter*

The charter for the Technical Review Panel on the Medicare Trustees Reports was signed by the Secretary on March 11, 2004. The charter will terminate on March 11, 2006, unless renewed by the Secretary.

**III. Copies of the Charter**

You may obtain a copy of the Secretary's charter for the Technical Review Panel on Medicare Trustees Reports by submitting a request to Andrew Cosgrove, 200 Independence Ave., SW., Washington DC, 20201, (202) 205–8681 or contact Andrew Cosgrove via e-mail at *andrew.cosgrove@hhs.gov.*

**Authority:** 42 U.S.C. 217a; section 222 of the Public Health Services Act, as amended.

**Michael J. O'Grady,**

*Assistant Secretary for Planning and Evaluation.*

[FR Doc. 04–9176 Filed 4–21–04; 8:45 am]

**BILLING CODE 4150–05–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

**[Program Announcement 04107]**

### Research Study To Assess the Risk of Blood Borne Transmission of Classic or Variant Creutzfeldt-Jakob Disease; Notice of Intent To Fund Single Eligibility Award

**A. Purpose**

The Centers for Disease Control and Prevention (CDC) announces the intent to fund fiscal year (FY) 2004 funds for a cooperative agreement program to continue an active, nationwide study begun in 1995 of recipients of blood products from primarily classic or possibly variant CJD. The Catalog of Federal Domestic Assistance number for this program is 93.283.

**B. Eligible Applicant**

Assistance will be provided only to the American Red Cross (ARC). The ARC, because of its earlier participation in the CJD Investigational Lookback Study, has unique possession of the personal identifiers of at least 95 living recipients of blood components from reported donors who subsequently developed CJD. The ARC is the only organization that has the complete relevant information on 237 such recipients who are now deceased.

In addition, the ARC has the personal identifiers on at least 25 donor cases of CJD for which recipient reports have been collected. It is this existing data that are critical to the strength of the statistical power and success of this project.

Further, the ARC is the only organization that has the professional affiliations already in place that will permit reasonable generalizations of the findings of this study to the entire nation.

**C. Funding**

Approximately $80,000 is available in FY 2004 to fund this award. It is expected that the award will begin on or before May 30, 2004, and will be made for a 12-month budget period within a project period of up to five years. Funding estimates may change.

**D. Where To Obtain Additional Information**

For general comments or questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341–4146, Telephone: 770–488–2700.

For technical questions about this program, contact: Mary Lerchen, Extramural Program Official, Centers for Disease Control and Prevention, National Center for Infectious Diseases, 1600 Clifton Road, NE., Mailstop C–19, Atlanta, GA 30333.

Dated: April 15, 2004.

**William P. Nichols,**

*Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention.*

[FR Doc. 04–9107 Filed 4–21–04; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### A Public Health Action Plan To Combat Antimicrobial Resistance (Part I: Domestic Issues): Meeting for Public Comment on the Antimicrobial Resistance Interagency Task Force Annual Report

The Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and National Institutes of Health (NIH) announce an open meeting concerning antimicrobial resistance.

*Name:* A Public Health Action Plan to Combat Antimicrobial Resistance (Part I: Domestic Issues): Meeting for Public Comment on the Antimicrobial Resistance Interagency Task Force Annual Report.

*Time and Date:* 1:30 p.m.–5 p.m., June 30, 2004.

*Place:* Hyatt Regency Bethesda, Waterford/Lalique Suite, One Bethesda Metro Center, 7400 Wisconsin Avenue at Old Georgetown Road, Bethesda, Maryland, 20814; telephone: 1–301–657–1234; Fax: 1–301–657–6453.

*Status:* Open to the public, limited only by the space available.

*Purpose:* To present the third annual report of progress by Federal agencies in accomplishing activities outlined in A Public Health Action Plan to Combat Antimicrobial Resistance (Part I: Domestic Issues), and solicit comments from the public regarding the annual report. The Action Plan serves as a blueprint for activities of Federal agencies to address antimicrobial resistance. The focus of the plan is on domestic issues.

*Matters to be Discussed:* The agenda will consist of welcome, introductory comments, followed by discussion of four focus areas in sequential plenary sessions lasting up to 45 minutes each. The four focus areas are: Surveillance, Prevention and Control, Research, and Product Development. Session leaders will give a 10 to 15 minute overview at the beginning of each session, then open the meeting for general discussion.

Comments and suggestions from the public for Federal agencies related to each of the focus areas will be taken under advisement by the Antimicrobial Resistance Interagency Task Force. The agenda does not include development of consensus positions, guidelines, or discussions or endorsements of specific commercial products.

The Action Plan, Annual Report, and meeting agenda will be available at *http://www.cdc.gov/drugresistance.* The public meeting is sponsored by the CDC, FDA, and NIH, in collaboration with seven other Federal agencies and departments involved in developing and writing A Public Health Action Plan to Combat Antimicrobial Resistance (Part I: Domestic Issues).

Agenda items are subject to change as priorities dictate.

Limited time will be available for oral questions, comments, and suggestions from the public. Depending on the number wishing to comment, a time limit of three minutes may be imposed. In the interest of time, visual aids will not be permitted, although written material may be submitted to the Task Force. Written comments and suggestions from the public are encouraged and can be submitted at the meeting or should be received by the contact person by regular mail or email listed below no later than July 31, 2004.

Persons anticipating attending the meeting are requested to send written notification to the contact person below by June 18, 2004, including name, organization (if applicable), address, phone, fax, and e-mail address.

*For Further Information Contact:* Ms. Vickie Garrett, Antimicrobial Resistance, Office of the Director, NCID, CDC, mail stop C–12, 1600 Clifton Road, NE, Atlanta, Georgia 30333; telephone 404–639–2603; fax 404–639–4197; or e-mail *aractionplan@cdc.gov.*

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for

CDC and the Agency for Toxic Substances and Disease Registry.

Dated: April 15, 2004.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 04–9103 Filed 4–21–04; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

### Submission for OMB Review; Comment Request

*Title:* OCSE–157 Child Support Enforcement Program Annual Data Report.

*OMB No.:* 0970–0177.

*Description:* The information obtained from this form will be used to report Child Support Enforcement activities to the Congress as required by law, to complete incentive measures and performance indicators utilized in the program, and to assist the Office of Child Support Enforcement in monitoring and evaluating State Child Support programs.

*Respondents:* State, local or tribal governments.

**Annual Burden Estimates**

| Instrument | Number of respondents | Number of responses per respondent | Average burden hours per response | Total burden hours |
|---|---|---|---|---|
| OCSE–157 | 54 | 1 | 4.0 | 216.0 |

*Estimated Total Annual Burden Hours:* 216.0.

*Additional Information:*

Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. E-mail address: *grjohnson@acf.hhs.gov.*

*OMB Comment:*

OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives if within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Attn: Desk Officer for ACF, E-mail address: *katherine_t._astrich@omb.eop.gov.*

Dated: April 18, 2004.

**Robert Sargis,**

*Reports Clearance Officer.*

[FR Doc. 04–9084 Filed 4–21–04; 8:45 am]

**BILLING CODE 4184–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### Nonprescription Drugs Advisory Committee and the Dermatologic and Ophthalmic Drugs Advisory Committee; Amendment of Notice

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Nonprescription Drugs Advisory Committee and the Dermatologic and Ophthalmic Drugs Advisory Committee. This meeting was announced in the **Federal Register** of March 30, 2004 (69 FR 16582). The amendment is being made to reflect changes in the introductory paragraph and in the following portions of the document: *Date and Time*, *Location*, *Agenda*, and *Procedure*; and to add a portion entitled "*Closed Committee Deliberations*.'' There are no other changes.

**FOR FURTHER INFORMATION CONTACT:** Dornette Spell-LeSane or Kimberly Littleton Topper, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 301–827–7001, e-mail *topperk@cder.fda.gov* or *spelllesaned@cder.fda.gov*, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington DC area), codes 3014512541 or 3014512534. Please call the Information Line for up-to-date information on this meeting.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of March 30, 2004, FDA announced that a meeting of the Nonprescription Drugs Advisory Committee and the Dermatologic and Ophthalmic Drugs Advisory Committee would be held on May 6 and May 7, 2004. On page 16582, in the first and second columns, the introductory paragraph, *Date and Time*, *Location*, *Agenda*, and *Procedure* portions of the meeting notice are amended; and a portion entitled "*Closed Committee Deliberations*'' is added to read as follows:

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

*Date and Time*: The meeting will be held on May 6, 2004, from 8 a.m. to 5:30 p.m. and May 7, 2004, from 8 a.m. to 3:30 p.m.

*Location*: On May 6, 2004, from 8 a.m. to 5:30 p.m. and May 7, 2004, from 8 a.m. to 11 a.m., the committee will meet at the Center for Drug Evaluation and Research Advisory Committee Conference Room (rm. 1066), 5630 Fishers Lane, Rockville, MD. On May 7, 2004, from 11 a.m. to 3:30 p.m., the two committees will meet separately at two locations. The Nonprescription Drugs Advisory Committee will remain at the previously listed location for its separate meeting. The Dermatologic and Ophthalmic Drugs Advisory Committee will meet at the Food and Drug Administration, Parklawn Building, Chesapeake Conference Room, third floor, 5600 Fishers Lane, Rockville, MD for its separate meeting.

*Agenda*: On May 6, 2004, from 8 a.m. to 5:30 p.m. and May 7, 2004, from 8 a.m. to 11 a.m., the committee will discuss efficacy and labeling issues for over-the-counter drug products used in the treatment of tinea pedis (interdigital)